Named after the hundred-eyed watchman of Greek myth, Argus watches the education landscape: spotting new opportunities, pressure-testing the ventures we're building, and tracing every read back to the real-world signals behind it.
The evidence library: the raw signals the pipeline is watching across the education ecosystem. Every idea is built from these.
Rural hospitals need trained people, tested backups, downtime procedures, clinical continuity planning, and staff who know what to do when an alert fires. A framework won’t substitute for that work, but it helps organize it and makes progress measurable. The post Rural US Healthcare Has A Cybersecurity Problem — CMS Funding Can Help Fix the Part No One Sees appeared first on MedCity News .
NOCD, a virtual provider for OCD, announced plans to expand its virtual intensive outpatient program for people with severe OCD nationwide. The post NOCD Announces Plans for National Expansion of Intensive Outpatient Therapy appeared first on MedCity News .
Immunology startup Infinimmune is developing antibody drugs with potential advantages over traditional monoclonal antibodies. The Series A financing will support two lead programs entering the clinic in atopic dermatitis. The post Infinimmune Secures $75M for a More Human Approach to Developing Better Antibody Drugs appeared first on MedCity News .
Tolerance for this abrasion is gone. It wastes time, drains staff capacity, drives up costs, and affects the patient experience. The post From Friction to Fix: Measuring What’s Breaking Payer-Provider Trust appeared first on MedCity News .
[Sponsored] A new report from Forrester offers a score card assessing health tech vendors on customer experience for healthcare organizations considering adopting them. The post Which Health Tech Companies Are Getting Customer Experience Right? appeared first on MedCity News .
The American College of Physicians is urging policymakers to expand access to obesity treatment and healthy foods while investing in prevention and research. The post How Policymakers Can Improve Obesity Treatment and Affordability, Per American College of Physicians appeared first on MedCity News .
Pathos AI struck a deal for rights to a bispecific antibody drug conjugate from Alphamab that could become first in a new class of cancer drugs. Separately, the startup began a partnership with AstraZeneca on a protein degrader from the pharma company’s cancer drug pipeline. The post Pathos Picks Up Two Cancer Drugs Poised for Clinical Development With AI Agents appeared first on MedCity News .
The future of health care innovation is technology that carries more of the load, so people don’t have to. The post Health Tech Promised Simplicity — Why Does It Feel Like More Work? appeared first on MedCity News .
[Sponsored] What if health plans could identify member decline before an avoidable hospitalization occurs? Real-time clinical visibility into long-stay SNF members uncovers risk earlier and drives better outcomes. The post From Blind Spots to Better Outcomes: How SNF Data Transparency Strengthens LTSS appeared first on MedCity News .
The gap between what technology can do and how much patients trust it won’t close on its own. Here are some design decisions that build trust — and some that quietly destroy it. The post The Trust Gap in Digital Health and AI Starts With Design — Here’s How to Close It appeared first on MedCity News .
Cushla and Clirinx, two Irish startups, are merging to give rare disease patients one continuous health and research record. The deal will pair Cushla’s patient-controlled EHR with Clirinx’s unique patient ID system so data no longer gets lost between doctors, hospitals and clinical trials. The post This Merger Wants to Prevent Rare Disease Patients from Losing Their Data appeared first on MedCity News .
HHS awarded $77 million in SAMHSA grants for substance use prevention and treatment, mental health, suicide prevention and crisis services. The post HHS Provides $77M in Grants for Substance Use Prevention, Mental Health appeared first on MedCity News .
GSK’s messenger RNA vaccine for seasonal influenza is designed to prompt an immune response to two proteins on the surface of the virus. That could be an advantage over Moderna’s recently approved mRNA flu shot, which addresses just one of those proteins. The post GSK’s Pivotal Test for mRNA Flu Vaccine Aims to Show Two Targets Are Better Than One appeared first on MedCity News .
Faster trials are not a vanity metric. They reflect an undeniable need: getting safe therapies to patients sooner. The post Breaking the Amendment Cycle: How Agentic AI Enables Smarter Clinical Trial Design and Operations appeared first on MedCity News .
August has seen a slew of executive hires, exits and layoffs across the healthcare industry. For instance, Humana, Merck and Mayo Clinic named new executives. There were also layoffs at organizations including MaineHealth, Cellares and Sharp HealthCare. The post Healthcare Moves: A Monthly Summary of Hires, Exits and Layoffs appeared first on MedCity News .
MedCity News’ new event for healthcare investors and corporate business development leads — Bullseye — hit the mark when it comes to provocative and thoughtful commentary. Here’s what was said in panels throughout the day. The post We Are Rats; If Pharma Could Be Brave … And Other Bullseye POVs You Won’t Hear at Other Events appeared first on MedCity News .
The FTC and the states of Utah and California sued Hims & Hers, alleging it improperly shared consumers’ health information and misled customers about billing, subscriptions and cancellations. The post Why Hims & Hers Is Embroiled in Yet Another Controversy, This Time with the FTC appeared first on MedCity News .
Johnson & Johnson also gains an exclusive option to acquire Sail Biosciences for $2.58 billion. The deal puts J&J in the mix of pharmaceutical companies developing next-generation cell therapies for applications in autoimmune diseases. The post J&J Joins Immune Reset Race, Paying $785M to Partner on Sail Bio Cell Therapy appeared first on MedCity News .
Interdisciplinary coordination between nephrologists, primary care providers, pharmacists, dieticians, and everyone who interacts with patients is essential to ensure patient education, improve adherence, and reduce medication errors. The post More Medications, Less Clarity: Strengthening Polypharmacy Support for CKD Patients appeared first on MedCity News .
The between a code that satisfies a payer and the information a physician needs to treat a person, is what nearly every healthcare AI tool is racing past. As we push these systems toward precision medicine and genomics, that gap stops being an annoyance and becomes a patient safety issue. The post The Code Gets You Paid — The Variant Gets You Treated appeared first on MedCity News .
[Sponsored] A new whitepaper by League highlights examples from collaborations with Baptist Health. The post Moving Beyond Reactive Healthcare: 5 Traits of Successful Healthcare Organizations appeared first on MedCity News .
AstraZeneca and Amgen drug Tezspire met the goals of a Phase 3 test in eosinophilic esophagitis (EoE), a chronic disorder whose only approved biologic therapy is Sanofi’s Dupixent. An approval for Tezspire in EoE would be its third indication, bolstering sales of the blockbuster product. The post AstraZeneca, Amgen Drug Moves Closer to Competing With Dupixent in a New Indication appeared first on MedCity News .
Datavant launched a new provider exchange platform, which replaces fax-based record requests with a digital workflow. It aims to give care teams real-time visibility into request status while easing the administrative burden on clinical staff. The post Datavant’s New Platform Could Cut Record Retrieval Time from Days to Hours appeared first on MedCity News .
It’s time we reignite treatment development for sepsis and other immune-mediated conditions that strike when patients are most vulnerable. The post Precision Medicine Transformed Oncology —It’s Time to Do the Same for Sepsis appeared first on MedCity News .
Consumer drug platforms and how they fit into the rise of the consumer in healthcare will be part of the conversation at INVEST Digital Health, scheduled for October 29 in Dallas. Register today! The post What Do the Latest Iteration of Consumer Drug Platforms Offer? appeared first on MedCity News .
SCAN Health Plan CEO Sachin Jain and Ascendiun CEO Paul Markovich argued that healthcare leaders share responsibility for the industry’s shortcomings and called for greater accountability and systemic reform. The post Who Broke the Healthcare System? appeared first on MedCity News .
Hospitals that see improved long-term results in behavioral health patients will be those that prioritize metrics aligned with their care pathways. The post Rethinking How Hospitals Measure Behavioral Health Success appeared first on MedCity News .
Groundbreaking new therapies have exciting potential to treat and cure diseases while minimizing burden on patients; however, they create major clinical, operational and financial implications that must be planned for years in advance. The post Four Ways Health Systems Should Plan for the Next Wave of Breakthrough Therapies appeared first on MedCity News .
Assured Health raised $19 million for its AI agents that verify provider credentials and manage insurance enrollment for health systems and group practices. The startup said it can cut a process that usually takes months down to days. The post Assured Health Secures $19M to Get Providers In-Network Faster with Agentic AI appeared first on MedCity News .
SCAN Health Plan and Costco are partnering to provide a suite of insurance products for seniors. The post SCAN, Costco Launch Medicare Partnership appeared first on MedCity News .
Ultragenyx Pharmaceutical’s Genglycos received accelerated FDA approval for glycogen storage disease type Ia, an inherited enzyme deficiency. It’s also the first approved gene therapy for Ultragenyx, which specializes in rare disease treatments. The post Ultragenyx Gene Therapy Becomes First FDA-Approved Treatment for Ultra-Rare Disease appeared first on MedCity News .
Why the flood of consumer wellness devices demands clear boundaries between lifestyle improvement and clinical diagnostics The post The Imperative of Distinguishing Medical-Grade Devices from Wellness Tech appeared first on MedCity News .
As adoption accelerates, organizations must ensure that the use of AI strengthens and not weakens accountability and patient safety. The post AI in Pharmacovigilance: Why Governance Will Define Success appeared first on MedCity News .
A court ruling struck down key parts of how regulators calculate the No Surprises Act’s qualifying payment amount, siding with the Texas Medical Association’s argument that the formula has historically favored payers in arbitration. The post Appeals Court Sides with Providers in No Surprises Act Pay Dispute appeared first on MedCity News .
Cotiviti launched an AI-powered coordination of benefits solution that uses enrollment data to identify and resolve coverage issues before claims are submitted. The post Cotiviti Launches AI Solution to Address Coordination of Benefits Issues appeared first on MedCity News .
Sangamo Therapeutics filed for Chapter 11 bankruptcy in June after its search for strategic alternatives failed to find a path forward for the company. PTC Therapeutics’ auction win brings a Sangamo gene therapy candidate for Fabry disease, a rare inherited disorder with few treatment options. The post PTC Therapeutics’ $211M Bid Wins Bankruptcy Auction for Sangamo Gene Therapy appeared first on MedCity News .
In healthcare, enterprises are moving slower than the hype cycle would lead you to believe. That said, they’re not moving slowly – they are saying yes to AI, as long as it can solve for specific workflow needs. The post Founders Should Stop Worrying If They’re “AI Enough” appeared first on MedCity News .
The FDA approved Moderna’s flu vaccine mFLUSIVA, a regulatory decision that comes six months after the agency refused to review the mRNA shot and then quickly reversed its position. But a recommendation from a Centers for Disease Control and Prevention advisory committee is key for payer coverage, and that committee has not met all year due to ongoing litigation. The post Moderna Gets FDA Approval for mRNA Flu Vaccine, But CDC Input Still Uncertain appeared first on MedCity News .
A new survey found that many employers are considering ICHRAs, though concerns about awareness, affordability and the individual insurance market continue to slow adoption. The post Report: What Employers Think About ICHRAs appeared first on MedCity News .
At MedCity News’ inaugural Bullseye conference in Chicago, Debunked Podcast co-hosts Arundhati Parmar and Samir Batra discussed recent CMS actions and Mayo Clinic’s former research director, who has filed a complaint against the medical center over how it’s deploying AI. The post Debunked Episode 29: CMS GLP-1 Drug Pilot Program, RPM Strategy Raise Questions appeared first on MedCity News .
The industry has made real progress in recognizing that oral health belongs at the center of whole-person care, but intent alone isn’t enough. To translate this vision into something tangible, the industry must invest in infrastructure that makes integration not only possible but scalable. The post Connecting the Dots: How Oral Health Can Enable Whole-Person Care appeared first on MedCity News .
Cold chain is a logistics problem — not just a throughput problem. Pharmacies must rethink their strategy, not just automate it. The post Should You Centralize Cold Chain Fulfillment? Only If You’ve Solved Distribution First appeared first on MedCity News .
Judi Health expanded its healthcare network to offer specialized virtual care for cancer, autoimmune and GI conditions while helping employers reduce overall healthcare costs. The post Judi Health Taps Color Health, WellTheory, Cylinder for Clinical Ecosystem appeared first on MedCity News .
A roundup of the seven most notable hospital mergers and acquisitions announced or completed this summer, including Prisma Health’s acquisition of Erlanger Health and Sanford Health’s purchase of North Memorial Health The post 7 Hospital Mergers from Summer 2026 appeared first on MedCity News .
Ultragenyx Pharmaceuticals’ apazunersen did not meet the goals of its Phase 3 test in Angelman syndrome, a rare genetic neurological disorder with no FDA-approved therapies. The disappointing result has some readthrough to Ionis Pharmaceuticals and Oak Hill Bio, each in clinical development with Angelman drugs designed to work in a similar way as Ultragenyx’s failed molecule. The post Ultragenyx Trial Failure Revives Debate About How to Treat a Rare Neuro Disorder appeared first on MedCity News .
This shift is not about replacing clinical care with tradition. It is about recognizing that healing in Native communities has always been deeply connected to culture. The post Healing Through Heritage: Why Culturally Grounded Recovery Matters on Tribal Lands appeared first on MedCity News .
A new report found that while more than 90% of health systems have deployed third-party AI tools, less than half have the infrastructure to properly test and validate them before they become embedded in patient care. The post Hospitals Are All In on AI, but Testing and Oversight Haven’t Caught Up appeared first on MedCity News .
Biohaven is outlicensing to SK Biopharmaceuticals global rights to opakalim, a Kv7-targeting small molecule in pivotal clinical testing for epilepsy. Biohaven gets non-dilutive financing for its pipeline while SK Bio gains another asset to potentially commercialize in the U.S. The post SK Bio Broadens U.S. Prospects, Licensing Late-Stage Epilepsy Drug From Biohaven appeared first on MedCity News .
When the healthcare system defaults to uncertainty, people delay care because it feels safer for their wallets. In some cases, people wait too long, leaving an ER visit as the path of least resistance. The post The Missing Piece in Lowering the Cost of Care: Predictability appeared first on MedCity News .
Crystalys’s dotinurad is currently in pivotal testing for gout, a prevalent inflammatory disorder with few treatment options. The drug has the same mechanism of action as a molecule that Sobi added to its pipeline through a $950 million acquisition. The post Crystalys Therapeutics Tacks On $130M for Pivotal Tests of Gout Drug appeared first on MedCity News .